Sociedad Argentina de Hematología

ISSN 2250-8309


Declaración de Conflictos de Interés

Cesión de Derechos de Autor

Se solicita enviar ambos formularios a:




Revista Argentina de Hematología


Volumen:    22    # Number : 2

Publication Date :    Mayo - Agosto    Year:    2018


Immunohematological finding anticipates refractoriness to treatment with daratumumab in a patient with multiple myeloma

Authors: Andrade Vera K, Fischman L, Bambés G, Bartolomeo S, Carreras Vescio LA

Abstract: Daratumumab (DARA) is a human monoclonal antibody that targets CD38. It is used for the treatment of patients with refractory/relapse multiple myeloma. DARA interferes with immunohematological tests, causing positive agglutination reactions in indirect antiglobulin tests, antibody screening tests and crossmatches, from the beginning of the treatment until several months after finished. We describe the case of a 65-years old patient with relapsed multiple myeloma treated with DARA. It was confirmed positivization in its immunohematological tests as planned, but evolving with a premature and unexpected negativization. The patient was refractory to this treatment. Thisatypical immunohematological finding could be dueto the development of anti-DARA antibodies.

Key words: daratumumab, multiple myeloma, anti-CD38 immunohematologic interference, inhibitor antibodies.

Pages : 185-187

  Resumen             pdf  

Julián Alvarez 146 - Ciudad Autónoma de Bs As - Argentina
(54-11) 4855-2452 / 2485